Stem cell therapy may be an alternative option for the treatment of ischemic cardiomyophaty as it replaces dead cells for functional cells, unlike conventional treatments. The aim of this study was to investigate the ability of human adipose tissue-derived stem cells to differentiate towards a cardiomyogenic phenotype in vitro using the demethylating agent 5-aza-2-deoxicytydine.